Search
forLearn
5 / 801 resultslearn ceramide 2
learn Glycine
learn Glycine
learn octapeptide-2
Research
5 / 1000+ resultsresearch 685 Modelling intrinsic and extrinsic cellular senescence in vitro with complex bioengineered human skin constructs
Bioengineered skin models aging well, useful for studying aging and testing treatments.
research Single-cell transcriptomics reveals lineage trajectory of human scalp hair follicle and informs mechanisms of hair graying
The study found new details about human hair growth and suggests that preventing a specific biological pathway could potentially treat hair graying.
research Immediate but Temporal Response: The Role of Distal Epithelial Cells in Wound Healing
research Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development
Blocking Wnt/β-catenin signaling with EGF receptor is necessary for proper hair growth.
research Flavonoids in safflower extract reduce cisplatin-induced damage to human follicle dermal papilla cells by inhibiting DNA damage and Rad17/Chk1/Cdc25C signaling
Safflower extract helps protect hair follicle cells from damage caused by chemotherapy.
Community Join
5 / 1000+ resultscommunity HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.